Publication:
In vivo assessments to detect antimalarial resistance

dc.contributor.authorMehul J. Dhordaen_US
dc.contributor.authorArjen M. Dondorpen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherNuffield Department of Clinical Medicineen_US
dc.contributor.otherAsia Regional Centreen_US
dc.date.accessioned2020-01-27T07:55:50Z
dc.date.available2020-01-27T07:55:50Z
dc.date.issued2019-01-01en_US
dc.description.abstract© Springer Science+Business Media, LLC, part of Springer Nature 2019. In vivo drug clinical trials are the gold standard for assessing the therapeutic efficacy of antimalarials. They must be conducted in a rigorous and standardized manner so that the resistance of antimalarial drugs can be compared both in time and in space. This chapter presents the methodology for conducting such clinical studies of antimalarials for the treatment of uncomplicated malaria and describes the logistical difficulties and limitations of this methodology. Finally it highlights the importance of such knowledge in preventing resistance, in prolonging the utility of existing antimalarial drugs, and in ensuring that all individuals and populations suffering from malaria get the right malaria treatment at the right time.en_US
dc.identifier.citationMethods in Molecular Biology. Vol.2013, (2019), 105-121en_US
dc.identifier.doi10.1007/978-1-4939-9550-9_8en_US
dc.identifier.issn19406029en_US
dc.identifier.issn10643745en_US
dc.identifier.other2-s2.0-85068860531en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/50363
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85068860531&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleIn vivo assessments to detect antimalarial resistanceen_US
dc.typeChapteren_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85068860531&origin=inwarden_US

Files

Collections